Stockscreener 앱 받기
10.73
0.00%
0.00
시간 외 거래:
1.90
-8.83
-82.29%
전일 마감가:
$10.73
열려 있는:
$11.46
하루 거래량:
7,255
Relative Volume:
0.29
시가총액:
$69.50M
수익:
$28.83M
순이익/손실:
$-13.34M
주가수익비율:
-7.0592
EPS:
-1.52
순현금흐름:
$-7.49M
1주 성능:
-2.45%
1개월 성능:
-17.46%
6개월 성능:
+271.28%
1년 성능:
+328.34%
1일 변동 폭
$10.47
$11.58
1주일 범위
$9.81
$11.58
52주 변동 폭
$1.44
$36.00
Exicure Inc Stock (XCUR) Company Profile
명칭
Exicure Inc
전화
847-673-1700
주소
2430 N. HALSTED ST., CHICAGO, IL
XCUR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| 0.625 | 0 | 0 | 0 | 0 | 0.00 | |
GOODO
Gladstone Commercial Corporation
|
20.26 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1555 | 349.69M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
MOBBW
Mobilicom Limited Warrants
|
0.2267 | 318.40M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
11.00 | 205.55M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
4.11 | 157.18M | 0 | 0 | 0 | 0.00 |
Exicure Inc Stock (XCUR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-12-13 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2020-12-18 | 개시 | BMO Capital Markets | Outperform |
| 2019-11-20 | 개시 | Guggenheim | Buy |
Exicure Inc 주식(XCUR)의 최신 뉴스
Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant | XCUR Stock News - GuruFocus
Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant - Business Wire
Geode Capital Management LLC Purchases Shares of 12,645 Exicure, Inc. (NASDAQ:XCUR) - Defense World
Exicure, Inc. (NASDAQ:XCUR) Sees Significant Drop in Short Interest - Defense World
Investors Can Still File Late Claims for Exicure $5.6M Settlement Payouts - TradingView
Why Exicure Inc. (XCUR) Soared on Monday - MSN
How To Trade (XCUR) - news.stocktradersdaily.com
Exicure, Inc. (NASDAQ:XCUR) Sees Large Drop in Short Interest - Defense World
Exicure Close to Finishing Patient Recruitment in Phase 2 Study of GPC-100 in Multiple Myeloma - MarketScreener
Exicure appoints new independent accounting firm By Investing.com - Investing.com India
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma - BioSpace
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study o - GuruFocus
Exicure appoints new independent accounting firm - Investing.com Australia
Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML) - BioSpace
New Clinical Trial: Exicure's GPC-100 Shows Promise in Fighting Acute Myeloid Leukemia - Stock Titan
How to Take Advantage of moves in (XCUR) - news.stocktradersdaily.com
Eli Lilly and Company (NYSE:LLY) and Exicure (NASDAQ:XCUR) Head to Head Analysis - Defense World
Short Interest in Exicure, Inc. (NASDAQ:XCUR) Grows By 58.5% - Defense World
Wednesday’s Insider Moves: Top Buys and Sells in US Stocks - Investing.com India
Wednesday’s Insider Moves: Top Buys and Sells in US Stocks By Investing.com - Investing.com UK
Trading (XCUR) With Integrated Risk Controls - news.stocktradersdaily.com
Major Investment Alert: HiTron Systems Inc. Boosts Stake in Exicure! - TipRanks
HiTron Systems acquires $8.7 million in Exicure stock By Investing.com - Investing.com Canada
HiTron Systems acquires $8.7 million in Exicure stock - Investing.com
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Exicure, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm - Business Wire
Exicure Inc Reports $9.7 Million Net Loss for Fiscal Year 2024 A - GuruFocus
Exicure Announces Presentation at Chardan’s 6th Annual Genetic Medicines Conference - Business Wire
Short Interest in Exicure, Inc. (NASDAQ:XCUR) Increases By 24.2% - Defense World
Exicure, Inc. Reports Full Year 2024 Financial Results - BioSpace
EXICURE, INC. SEC 10-K Report - TradingView
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Exicure, Inc. Investors to Secure Counsel Before Important February 11 Deadline in Securities Class Action – XCUR - Business Wire
Pre-Market Momentum: Exicure (XCUR) Shares Rise After Key Approval - Stocks Telegraph
When (XCUR) Moves Investors should Listen - Stock Traders Daily
Exicure Gets Patent in Australia for Potential Cancer Treatment Combination -March 14, 2025 at 04:32 am EDT - Marketscreener.com
Exicure secures Australian patent for cancer treatment - Investing.com Australia
Exicure, Inc. Announces Issuance Of New Patent In Australia -March 13, 2025 at 05:39 pm EDT - Marketscreener.com
Exicure announces issuance of new patent in Australia - TipRanks
Exicure secures Australian patent for cancer treatment By Investing.com - Investing.com South Africa
Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia - Business Wire
Pre-market Movers: HCTI, HEPA, ZYXI, SYRS ... - RTTNews
Exicure announces board member departures, transitions By Investing.com - Investing.com Australia
(XCUR) Technical Pivots with Risk Controls - Stock Traders Daily
Exicure announces board member departures, transitions - Investing.com
Exicure, Inc. (NASDAQ:XCUR) Short Interest Down 16.2% in February - Defense World
Where are the Opportunities in (XCUR) - Stock Traders Daily
Exicure (NASDAQ:XCUR) Stock Price Down 1.6% – Time to Sell? - Defense World
Exicure Stock Soars Over 25% On Acquisition Of GPCR Therapeutics’ U.S. Unit: Retail Chatter Spikes - MSN
Exicure Inc (XCUR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):